Literature DB >> 7927713

Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro.

J A Chappel1, A F Egan, E M Riley, P Druilhe, A A Holder.   

Abstract

Merozoite surface protein 1, one of the major surface proteins of the invasive blood stage of the malaria parasite, is a prime candidate for the development of a vaccine against the human disease. Previously, monoclonal antibodies which both inhibited the growth of Plasmodium falciparum in vitro and bound to the first of two epidermal growth factor-like modules located near the carboxy terminus of the protein had been identified. In this study, we have used affinity chromatography on a recombinant fusion protein corresponding to the first epidermal growth factor-like module in P. falciparum merozoite surface protein 1 to prepare antibody induced by natural infection. The antibody was purified from the total immunoglobulin G fraction of adult West African donors, shown to passively confer immunity against falciparum malaria. Such affinity-purified antibodies were shown to recognize the native protein by a number of separate criteria and to block the binding of an inhibitory monoclonal antibody, but they failed to inhibit parasite invasion in an in vitro growth assay. These results indicate that antibody alone is not sufficient to interfere with erythrocyte invasion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927713      PMCID: PMC303134          DOI: 10.1128/iai.62.10.4488-4494.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Comparison of the carboxy-terminal, cysteine-rich domain of the merozoite surface protein-1 from several strains of Plasmodium yoelii.

Authors:  T M Daly; J M Burns; C A Long
Journal:  Mol Biochem Parasitol       Date:  1992-06       Impact factor: 1.759

2.  Kinetic constraints on the development of a malaria vaccine.

Authors:  A Saul
Journal:  Parasite Immunol       Date:  1987-01       Impact factor: 2.280

3.  A single amino acid determines the specificity of a monoclonal antibody which inhibits Plasmodium chabaudi AS in vivo.

Authors:  P G McKean; K O'Dea; K N Brown
Journal:  Mol Biochem Parasitol       Date:  1993-12       Impact factor: 1.759

4.  Topography of epitopes on a polymorphic schizont antigen of Plasmodium falciparum determined by the binding of monoclonal antibodies in a two-site radioimmunoassay.

Authors:  C F Wilson; R Anand; J T Clark; J S McBride
Journal:  Parasite Immunol       Date:  1987-11       Impact factor: 2.280

5.  Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1).

Authors:  L H Miller; T Roberts; M Shahabuddin; T F McCutchan
Journal:  Mol Biochem Parasitol       Date:  1993-05       Impact factor: 1.759

6.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

7.  Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae.

Authors:  D C Kaslow; G Hui; S Kumar
Journal:  Mol Biochem Parasitol       Date:  1994-02       Impact factor: 1.759

8.  The role of calcium in the invasion of human erythrocytes by Plasmodium falciparum.

Authors:  N McCallum-Deighton; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1992-02       Impact factor: 1.759

9.  Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

Authors:  M J Blackman; I T Ling; S C Nicholls; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

10.  Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

Authors:  M J Blackman; T J Scott-Finnigan; S Shai; A A Holder
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  8 in total

1.  Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.

Authors:  D Dodoo; T G Theander; J A Kurtzhals; K Koram; E Riley; B D Akanmori; F K Nkrumah; L Hviid
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion.

Authors:  Ute Woehlbier; Christian Epp; Fiona Hackett; Michael J Blackman; Hermann Bujard
Journal:  Malar J       Date:  2010-03-18       Impact factor: 2.979

3.  Relationship between maternally derived anti-Plasmodium falciparum antibodies and risk of infection and disease in infants living in an area of Liberia, west Africa, in which malaria is highly endemic.

Authors:  B Høgh; N T Marbiah; P A Burghaus; P K Andersen
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

4.  Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.

Authors:  Danny W Wilson; Freya J I Fowkes; Paul R Gilson; Salenna R Elliott; Livingstone Tavul; Pascal Michon; Elija Dabod; Peter M Siba; Ivo Mueller; Brendan S Crabb; James G Beeson
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

5.  Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate--Tackling the Cocktail Challenge.

Authors:  Alexander Boes; Holger Spiegel; Nadja Voepel; Gueven Edgue; Veronique Beiss; Stephanie Kapelski; Rolf Fendel; Matthias Scheuermayer; Gabriele Pradel; Judith M Bolscher; Marije C Behet; Koen J Dechering; Cornelus C Hermsen; Robert W Sauerwein; Stefan Schillberg; Andreas Reimann; Rainer Fischer
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.

Authors:  Christian Roussilhon; Claude Oeuvray; Christine Müller-Graf; Adama Tall; Christophe Rogier; Jean-François Trape; Michael Theisen; Aissatou Balde; Jean-Louis Pérignon; Pierre Druilhe
Journal:  PLoS Med       Date:  2007-11-13       Impact factor: 11.069

7.  Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies.

Authors:  J A Guevara Patiño; A A Holder; J S McBride; M J Blackman
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

8.  The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies.

Authors:  Roseangela I Nwuba; Olugbemiro Sodeinde; Chiaka I Anumudu; Yusuf O Omosun; Alexander B Odaibo; Anthony A Holder; Mark Nwagwu
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.